US Bancorp’s Acorda Therapeutics ACOR Stock Holding History

US Bancorp’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1	Closed	-$2K	–	3680
2018 Q4	$2K	Hold	1	–	–	﹤0.01%	3448
2018 Q3	$2K	Hold	1	–	–	﹤0.01%	3517
2018 Q2	$5K	Hold	1	–	–	﹤0.01%	3338
2018 Q1	$4K	Hold	1	–	–	﹤0.01%	3388
2017 Q4	$4K	Hold	1	–	–	﹤0.01%	3383
2017 Q3	$4K	Hold	1	–	–	﹤0.01%	3325
2017 Q2	$3K	Sell	1 -1	-50%	-$1.98K	﹤0.01%	3350
2017 Q1	$4K	Hold	2	–	–	﹤0.01%	3281
2016 Q4	$4K	Buy	+2	New	+$4.75K	﹤0.01%	3266
2016 Q3	–	Sell	-1	Closed	-$2.98K	–	3644
2016 Q2	$4K	Hold	1	–	–	﹤0.01%	3251
2016 Q1	$4K	Hold	1	–	–	﹤0.01%	3240
2015 Q4	$6K	Buy	+1	New	+$4.37K	﹤0.01%	3201
2015 Q3	–	Sell	-6	Closed	-$23.3K	–	3695
2015 Q2	$24K	Sell	6 -2	-25%	-$7.73K	﹤0.01%	2870
2015 Q1	$32K	Sell	8 -5	-38%	-$22.9K	﹤0.01%	2748
2014 Q4	$62K	Buy	13 +12	+1,200%	+$51.5K	﹤0.01%	2411
2014 Q3	$6K	Sell	1 -1	-50%	-$3.75K	﹤0.01%	3172
2014 Q2	$7K	Hold	2	–	–	﹤0.01%	3151
2014 Q1	$8K	Buy	2 +1	+100%	+$4.04K	﹤0.01%	3104
2013 Q4	$5K	Buy	+1	New	+$3.9K	﹤0.01%	3142
2013 Q3	–	Hold	0	–	–	–	3355
2013 Q2	–	Hold	0	–	–	–	3248

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

US Bancorp's ACOR Position: Q1 2019 in Review

US Bancorp sold out of Acorda Therapeutics (ACOR) in Q1 2019, closing a stake of 1 share — an estimated $2K sold.

US Bancorp first reported a position in ACOR in Q4 2013 and held it in 19 quarters. The position peaked at $62K in Q4 2014. 184 funds tracked by Wall St. Rank hold ACOR as of Q1 2019.

US Bancorp reported no remaining Acorda Therapeutics position as of Q1 2019 after selling out during the quarter.
US Bancorp sold 1 Acorda Therapeutics share in Q1 2019, an estimated $2K.
US Bancorp first reported a position in Acorda Therapeutics in Q4 2013 and held it in 19 quarters.
US Bancorp's Acorda Therapeutics position peaked at $62K in Q4 2014.
184 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2019.

Based on US Bancorp's 13F filing for Q1 2019, filed 8 May 2019.